Anti-CD3 antibodies and uses thereof

US12304953B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• Francois Gaudet · Princeton, US
• Jill Giles-Komar · Downingtown, US
• Bradley J. Heidrich · Gilbertsville, US
• Chichi Huang · Malvern, US
• Colleen Kane · Radnor, US
• Ronan McDaid · Eagleville, US
• Jennifer Nemeth-Seay · Fort Washington, US

Key dates

• Filing date: Mar 8, 2023
• Grant date: May 20, 2025
• Expiry date: Mar 8, 2043

Classification

• Technology area (CPC —): General

Abstract

The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.